NCT04062448 - A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 25, 2019

Primary Completion Date

August 24, 2021

Study Completion Date

March 2, 2023

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG

Ibrutinib

Ibrutinib 420 mg will be administered orally.

DRUG

Rituximab

Rituximab 375 mg/m\^2 will be administered intravenously.

Trial Locations (9)

Kameda Medical Center, Chiba

National Cancer Center Hospital, Chūōku

National Hospital Organization Kumamoto Medical Center, Kumamoto

Matsuyama Red Cross Hospital, Matsuyama

Nagoya City University Hospital, Nagoya

Osaka Metropolitan University Hospital, Osaka

Osaka University Hospital, Suita

National Hospital Organization Disaster Medical Center, Tachikawa

University of Tsukuba Hospital, Tsukuba